临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 50-22-6

Corticosterone (NSC-9705)

中文名称:肾上腺酮
CAS号:50-22-6
分子式: C21H30O4 分子量: 346.46
产品形式: free base
研发状态: Recruiting
研发用途: Acne Vulgaris
研究机构: Marmara University
研发日期: September 15 2022
研发阶段: --
Corticosterone (NSC-9705, 17-deoxycortisol, 11β,21-dihydroxyprogesterone), the major stress hormone, is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

CAS: 501951-42-4

SB705498

中文名称:N-(2-溴苯基)-N'-[(3R)-1-[5-(三氟甲基)-2-吡啶基]-3-吡咯烷基]脲
CAS号:501951-42-4
分子式: C17H16BrF3N4O 分子量: 429.23
产品形式: free base
研发状态: Completed
研发用途: Rhinitis
研究机构: GlaxoSmithKline
研发日期: Apr-11
研发阶段: Phase 2
SB705498 is a TRPV1 antagonist for hTRPV1, antagonizes capsaicin, acid, and heat activation of TRPV1 with IC50 of 3 nM, 0.1 nM and 6 nM, shows a degree of voltage dependence, exhibits >100-fold selectivity for TRPV1 over TRPM8. Phase 2.

CAS: 50-18-0

Cyclophosphamide

中文名称:环磷酰胺
CAS号:50-18-0
分子式: C7H15Cl2N2O2P 分子量: 261.09
产品形式: Free base
研发状态: Active not recruiting
研发用途: Breast Cancer Female
研究机构: Mansoura University
研发日期: December 25 2023
研发阶段: Phase 2
Cyclophosphamide(NSC 26271,Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cytophosphane) is a nitrogen mustard alkylating agent from the oxazophorines group.

CAS: 501-36-0

Resveratrol (SRT501)

中文名称:白藜芦醇
CAS号:501-36-0
分子式: C14H12O3 分子量: 228.24
产品形式: free base
研发状态: Recruiting
研发用途: Wheezing; Recurrent Respiratory Tract Infections
研究机构: Noos S.r.l.
研发日期: November 1 2022
研发阶段: Not Applicable
Resveratrol (SRT501, trans-Resveratrol) has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.

CAS: 5011-34-7

Trimetazidine

中文名称:曲美他嗪
CAS号:5011-34-7
分子式: C14H22N2O3 分子量: 266.34
产品形式: Free Base
研发状态: Completed
研发用途: Platelet Dysfunction Due to Drugs
研究机构: The University of The West Indies
研发日期: July 1 2018
研发阶段: Phase 2
Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity and results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation.

CAS: 500-92-5

Proguanil

中文名称:氯胍
CAS号:500-92-5
分子式: C11H16ClN5 分子量: 253.73
产品形式: Free Base
研发状态: Completed
研发用途: Malaria
研究机构: Medicines for Malaria Venture; Richmond Pharmacology Limited
研发日期: April 4 2019
研发阶段: Phase 1
Proguanil (chlorguanide, chloroguanide) is a prophylactic antimalarial drug. It inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines, which are essential for DNA synthesis and cell multiplication.